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Abstract: Chagas disease (CD), which mostly affects underprivileged people, has turned into one 9 
of Latin America’s main public health problems. Prevention of the disease requires early diagnosis, 10 
initiation of therapy, and regular blood monitoring of the infected individual. However, the majority 11 
of the infections go undiagnosed because of general mild symptoms and lack of access to medical 12 
care. Therefore, more affordable and accessible detection technologies capable of providing early 13 
diagnosis and parasite load measurements in settings where CD is prevalent are needed to enable 14 
enhanced intervention strategies. This review discusses currently available detection technologies 15 
and emerging biosensing technologies for a future application to CD. Even if biosensing 16 
technologies still require further research efforts to develop portable systems, we arrive to the 17 
conclusion that biosensors could improve diagnosis and the patients’ treatment follow-up, in terms 18 
of rapidity, small sample volume, high integration, ease of use, real-time and low cost detection 19 
compared to current conventional technologies. 20 
Keywords: Chagas disease, biosensors, detection technologies, diagnosis, neglected diseases. 21 
1. Introduction 22 
Chagas disease (CD), discovered in 1909 by the Brazilian physician Carlos Chagas (1), nowadays 23 
has turned into one of Latin America’s main public health problems (2). Based in disability-adjusted 24 
life-years as a measure of disease burden, CD figure as the most important parasitic vector-borne 25 
illness in the Region of Americas, seven times higher than Malaria and up to three times more than 26 
Dengue (3), and yet it is still absent in the agenda of the public health policies and practices of 27 
many endemic countries (4, 5). More generally, ranks fourth in mortality and eighth in morbidity 28 
Manuscript
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among world neglected tropical diseases (6), and is estimated that between eight and eleven 29 
million people are infected, while 100 million are at risk of acquiring the disease; the main cause 30 
being to live in proximity with disease vectors (7). CD is caused by the parasitic presence of the 31 
Trypanosoma cruzi in the organism, which is mainly transmitted by contamination with infected 32 
feces of blood-sucking triatomine vectors during a human blood meal. Nevertheless, it can also be 33 
transmitted through blood transfusions, organ transplants, infected mothers to their unborn 34 
children and ingestion of contaminated food (i. e. Oral transmission; WHO, 2002). Although disease 35 
progression can be associated with the mechanism of infection, with oral transmission causing the 36 
most severe outbreaks (9), people living at risk regions are susceptible to polyparasitism (i.e. 37 
Coinfections and superinfections with different strains of T. cruzi), with unknown effects in the 38 
variability of the disease progression and response to treatments (10). 39 
CD mostly affects underprivileged people and the majority of the T. cruzi infections go undiagnosed 40 
because of general mild symptoms and lack of access to medical care (11). Due to this fact, CD is 41 
considered as a Neglected Tropical Disease whose improvement in diagnosis and treatment today 42 
requires research and development efforts with non-profit interests. The highest prevalence of 43 
Chagas disease has been reported in Bolivia (6.75–15.4 %), followed by Paraguay (0.69–9.3 %), 44 
Panama (0.01–9.02 %), Brazil (0.8–1.30 %), Mexico (0.5–6.8 %) and Argentina (4.13–8.2 %) 45 
(12). Citing a case, this disease causes almost 6% of the annual deaths in Mexico and the 46 
seroprevalence can roughly be estimated at least in 3% due to a lack of active epidemiological 47 
surveillance (most cases are detected during blood screening procedures in blood banks). Yet, less 48 
than 0.5% of the infected individuals have access to treatment in this country as a result of 49 
anachronisms in the normativity, among other failures in the public health system (13). 50 
Even if CD mainly affects tropical countries, with nowadays ease of traveling and migration, other 51 
countries are also being affected by this infection (14). Several cases have been reported in USA, 52 
Canada, Europe and in Western Pacific regions like Japan and Australia (14–16). Notably, CD 53 
continues to be an inconspicuous public health problem, with limited medical awareness, either 54 
because it is commonly targeted in people with relatively low medical access or because it can 55 
currently occur in unexpected regions. Thus, the treatment of CD urgently needs to generalize and 56 
standardize diagnostic procedures. 57 
Biosensors are relatively new analytical devices that can help to detect the presence of specific 58 
compounds and pathogens in liquid environments and complex mixtures like: water and blood 59 
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serum. Although these devices have been formerly used in the alimentary industry (mostly to 60 
detect toxins and infectious pathogens), they are been increasingly used to diagnose human 61 
diseases (17). Therefore, these devices can be employed for the diagnosis of CD. The development 62 
of biosensors requires a biological active component to be immobilized onto the surface of a 63 
transducer. The selective recognition layer, towards T. cruzi specific antigens present in patients' 64 
blood serum, can selectively detect the target analyte generating a signal response in the sensor 65 
(see Figure 1). Depending on their transducing principle biosensors can be electrochemical, 66 
acoustic or optic. 67 
In this work, we firstly introduce a brief description of the disease. Secondly, we present a review 68 
of biosensor technologies whose applicability to diagnose CD has been investigated. Finally, we 69 
mention the benefits and drawbacks of applying biosensors as solutions to this major public health 70 
issue and the infrastructure required to conduct biosensor experiments for this application. 71 
2. Brief description of CD and current needs 72 
CD passes through two successive stages: an acute phase and a chronic phase. The acute phase 73 
occurs at the following 6-8 weeks after infection. The acute phase is followed by the chronic phase 74 
of CD, which lasts for the rest of the life of the infected individual, and has different forms. In the 75 
 
Figure 1. General scheme of a biosensor detection strategy. A biosensor is composed of a biochemical 
interface where specific bio-species are absorbed; a transducer which translates the recognition event to 
another physical response that can be measured and an electronic system which acquires and records the 
signal. 
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indeterminate form, an equilibrium between the parasite and the immunological response of the 76 
infected individual is reached and most infected patients appear healthy, with no evidence of organ 77 
damage that could be found by current standard methods of clinical diagnosis (8). About 50–70% 78 
of infected individuals will remain in this condition for the rest of their lives. However, several years 79 
after the chronic phase has started, 10–40% of infected individuals will pass to the cardiac form of 80 
the disease and will develop injuries of various organs, mainly the heart, the digestive system, and 81 
occasionally, the peripheral nervous system (8, 18). These important symptomatic changes occur 82 
10–20 years after the acute phase of the disease and include a broad range of types of damage. 83 
The clinical manifestations vary from mild symptoms to heart failure and, frequently, sudden 84 
cardiac death (18). The acute phase of CD is recognized only in an estimated 1–2% of all 85 
individuals acquiring the infection (8) due to a lack of access to sufficient medical care. Thus, more 86 
than any other parasitic disease, CD is closely related to social and economic development. 87 
Paradoxically, acute phase is the most appropriate period for drug treatment, showing relatively 88 
high levels of sero-conversion, while organ damage is prevented (19). Conversely, it has been 89 
shown that drug treatment with Trypanocidal therapy in patients with established Chagas 90 
cardiomyopathy, can cause seroconversion, but does not stop cardiac clinical deterioration (20). 91 
Given that no vaccine is currently available to prevent CD, vector control, diagnosis tests, 92 
opportune drug treatment, and clinical follow-up are the most effective methods to fight against 93 
the disease (21). Nevertheless, all these measures suffer of several hindrances imposed by the 94 
synergistic negative effects of diverse vulnerability components of CD risk, such as ecological 95 
factors (i.e. land-use changes) -that are broadening the contact zones between humans and 96 
parasites (Lopez-Cancino et al., 2015)-, the chronic failure of health care policies hindering the 97 
reduction of CD incidence (5), the limited awareness of physicians (22), and several socio-cultural 98 
practices that perpetuate CD exposure in endemic regions (23). Health policies to control/reduce 99 
vectorial exposure to CD in Latin America are challenged for the relatively high diversity of vectors 100 
that shows a broad environmental tolerance. Likewise, a wide territory of America is suitable for CD 101 
vectorial transmission (24–27). 102 
In order to face the epidemiological challenges due to the increasing complexity of interactions 103 
among the transmission routes of T. cruzi in endemic and non-endemic countries, access to early 104 
diagnostic and treatment seems as the most cost-efficient ways to reduce the CD burden (11). 105 
Several paths of scientific advances and discoveries envisage an optimistic future to reduce CD 106 
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burden coming from a better understanding of CD transmission and management toward its 107 
interruption (28). The fact that the World Health Organization (WHO) has made a commitment with 108 
Bill and Melinda Gates Foundation and other stakeholders to control the most neglected diseases by 109 
2020, including CD among them, opens an opportunity window to orientate research priorities. This 110 
commitment, launched in 2012, was called the London Declaration 111 
(http://www.unitingtocombatntds.org/). However, claims have been raised to urge implicated 112 
organizations to set the needed measures to reach these goals, among which improved diagnosis 113 
(i.e. precision and accessibility) seems as one of the most important first steps (5). 114 
Blood banks in endemic countries require fast and secure screening method for small and medium 115 
health facilities, since screening for CD is mandatory in some endemic countries (8). Several 116 
countries do not have an active program for CD detection and depend only for the blood bank 117 
reports. The most important reason of this fact is the low feasibility to detect Chagas in patients. 118 
Since, CD do not produce particular symptoms, there are not incentives from society. Nevertheless, 119 
the bug bite is quite notorious and people can suspect that they are infected with T. cruzi when a 120 
chinchoma1 appears. In such cases, people can search medical assistance and be subjects of a 121 
blood test. 122 
Climate change and global warming increase the risk of rising CD burden in some regions. Climate 123 
change impacts on vector-borne diseases (29) and is undoubtedly detonating variables that make 124 
the CD transmission become potentially dangerous, as the WHO points out (30). Nevertheless, the 125 
incidence of CD can be greatly reduced by residual insecticide-based vector control programs that 126 
decrease the populations of the transmitting vectors and by improving housing (31). 127 
3. Current detection technologies and their limitations 128 
Currently, laboratory methods are employed to diagnose CD. Depending on the patients’ phase of 129 
infection some are more convenient than others. During the acute phase of CD, a large number of 130 
parasites are present in the peripheral blood and can be diagnosed by direct microscopical 131 
observation of fresh blood (parasitological test). However, for the chronic phase of CD the 132 
diagnosis is not possible, due to the scarce parasitemia. Therefore, the immunodiagnosis is widely 133 
used since nearly all T. cruzi-infected individuals in the chronic phase develop antibodies against 134 
the complex antigenic mixture of the parasite (8). 135 
                                               
1 Name of the inflammatory injury after a bug bite. 
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Several immunodiagnosis tests are available, but mainly three conventional tests are widely used: 136 
indirect haemagglutination (IHA), indirect immunofluorescence (IIF) and Enzyme Linked Immuno 137 
Assay (ELISA). These tests present several limitations such as: (i) cross-reactivity with other 138 
parasites; (ii) not 100% of sensitivity; (iii) the need to be performed in a laboratory; and (iv) a 139 
long time is required to obtain the results. IHA test results can be obtained in about two hours, 140 
whereas IIF results can be obtained after numerous steps in two hours and ELISA takes several 141 
hours to carry out, including prior sensitization of microplates with T. cruzi antigens for about 12 142 
hours (6). All these tests have to be performed in centralized laboratories; some of them require 143 
sophisticated equipment and skilled technicians. Since none of these tests have a sensitivity of 144 
100%, the WHO recommends conducting at least two conventional tests for a definitive diagnosis 145 
of T. cruzi infection (8). 146 
More recently, non-conventional tests, like rapid lateral flow (RLF) tests, are commercially available 147 
in the market to detect T. cruzi infection using whole blood, serum or plasma (Sánchez-Camargo et 148 
al. 2014). These tests are based in different tests principles: immunochromatography, particle 149 
agglutination, immunofiltration or immunodot. They provide fast results (between 5 to 60 min 150 
reading times) without the need of electrical equipment and they require low volume samples (5 to 151 
150 μl). However, the sensitivities and specificities of such tests are lower than that of conventional 152 
tests and they only provide qualitative or semi-quantitative results, which prevents obtaining 153 
important test information like genetic lineage of the T. cruzi (32) and the immunoreaction 154 
kinetics. 155 
From a prospective point of view, it is important to discuss about another kind of technology, which 156 
could be deployed for Chagas Disease diagnosis in the near future. Over the last decade, Shear-157 
Horizontal (SH) Surface Acoustic Wave (SAW) immunosensors (Love-SAW with a guiding layer) 158 
have been developed for the diagnosis of various diseases (33). Such immunosensors exhibit a 159 
high sensitivity and a very low limit of detection (in the order of pg/μl of blood serum). This 160 
technology give very relevant results for the detection of antibodies, specific to certain diseases 161 
(34). The only drawback of this technology is that a residual frequency or phase shift always 162 
remains, which is induced by non-specific mass effects, i.e. a shift which does not correspond to 163 
specific antigen-antibody interactions on the sensor surface (34). In order to drastically reduce or 164 
avoid cross-reactions with other type of interactions that may lead to false positives, Rayleigh-SAW 165 
generation, on the same piezoelectric substrate, seems to be very promising (35). In addition, 166 
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these waves can be used to generate fast fluid actuation to improve mixing and desorption 167 
promoting faster molecular interactions. Indeed, Rayleigh-SAW liquid effects can induce intense 168 
recirculation, actuation, heating or atomization, depending on the mechanical power conveyed by 169 
these acoustic waves (36, 37). This recirculation can allow to re-suspend all non-specific species 170 
that could settle and lead to non-specific responses. 171 
4. Biosensing research efforts for Chagas diagnosis 172 
Biosensors that have been investigated for the diagnosis of CD can be classified into 173 
electrochemical -where amperometric (38–41) and impedimetric (42) sensors can be found- and 174 
optical -where mainly Surface Plasmon Resonance (SPR) transducers (6) are found. Biosensors 175 
could provide the benefits presented in Table 1 in comparison with other currently employed 176 
techniques for the diagnosis of CD. 177 
Pumpin-Ferreira et al., in 2005, reported a biosensor for the diagnosis of CD (38). It consisted on 178 
an amperometric immunosensor. This biosensor required an electrochemical interaction and, 179 
therefore, a potensiostat-galvanostat was required to conduct the measurements. Potensiostats are 180 
powerful equipment, but they are large and heavy for a final portable biosensing system. Hence, 181 
other electronics for biosensors characterization should be developed which provide higher 182 
miniaturization and integration capabilities for portable systems. 183 
Recently, Luz et al. (2015) presented the first biosensor for the diagnosis of CD based on SPR 184 
transducers (6). They obtained the parameter related to the presence of antibodies anti-T. Cruzi 185 
found in human serum in approximately 20 min. SPR transducing principle requires an optical 186 
source for the laser generation and the integration of this source to the equipment, currently, leads 187 
to high volume and heavy apparatus, only suitable for laboratory tests. Moreover, even if optical 188 
biosensors can be very sensitive, the cost of SPR equipment is higher than USD $50,000 and for 189 
this reason, not many researchers can afford such systems (43). 190 
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 191 
 192 
Table 1. Some methods for the diagnosis of CD. 193 
Methods Drawbacks Benefits References 
Selective Media  Microorganism needs to overgrowth fast 
 Long time to yield results 
 Needs a laboratory 
 Needs an aseptic work area 
 Needs trained personnel 
 Tedious procedure 
+ Cheap 
+ Easy to perform 
(44, 45)  
 
ELISA  Requires highly qualified personnel 
 Consumes a lot of time 
 Needs a laboratory 
 Expensive 
+ High selectivity and sensitivity 
+ Improves the time required to yield results 
+ It works well for samples without interfering 
molecules 
(44–49) 
 
Quantitative PCR  Expensive 
 Needs trained personnel 
 Needs a laboratory 
 Difficult to perform 
+ High selectivity and sensitivity 
+ Improving the time required to yield results 
(45) 
(47–49) 
Rapid test  Specificity 96.8%.  
 Just qualitative results.  
 The method needs a tube, a measured 
volume of sample and reagent 
 Can present false positive 
+ 15-25 min 
+ High sensitivity of 99.5 % 
+ Low cost (less than $2 to the end user) 
(7, 50) 
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 194 
 195 
 196 
 197 
Biosensors  Not commercially available 
 Large dimensions (currently) 
 Needs a laboratory 
 Further research and development is 
required for portable systems 
 High research cost 
 
+ No need of an aseptic working area 
+ Fast (real-time) 
+ Easy to perform. Not need of trained personnel 
+ In situ simple preparation 
+ High analytical specificity 
+ Reduction of reagents consumption 
+ Reduced analysis time 
+ High reliability 
+ High sensitivity 
+ Integration of multiple processes in a single device 
+ Possible automation 
+ Low cost of fabrication 
(6) 
(38–42) 
(17), 
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5. Biosensors and their contribution to reduce CD burden 198 
An ideal serological test should be easy to perform in a single step, fast, cheap, require no special 199 
equipment or refrigeration reagents and should have a sensitivity and specificity of 100%. Such a 200 
test does not exist currently for the diagnosis of CD. Hence, new technologies, which combine, 201 
robustness, simplicity, portability and rapidity with an effective sensitivity and selectivity could 202 
contribute to more efficiently diagnose CD. There are evidences that show that biosensors could 203 
meet most of these attributes for this application (6, 38). Biosensors could improve the diagnosis 204 
and the patients’ treatment follow-up, in terms of rapidity, real-time and low cost detection 205 
compared to current detection technologies like Polymerase Chain Reaction (PCR) and ELISA. In 206 
addition, the use of biosensors offers significant advantages like: small fluid volume manipulation, 207 
a high integration capability that facilitates the development of portable devices and ease of use. 208 
This should allow their use by non-specialized personnel in non-centralized laboratories (17). 209 
Nevertheless, further research efforts are needed to achieve a biosensing portable device for CD 210 
diagnosis. 211 
The expected features of biosensors are high selectivity and sensitivity, real-time label-free 212 
monitoring, easy to use, reliability, high miniaturization capabilities and low cost. Biosensors based 213 
on optical and acoustic wave sensing technologies could meet these requirements in a near future 214 
and seem to be very promising tools for this application. Such devices will lead to more sensitive 215 
tests at lower reagent concentrations, allowing biosensing system users to: i) reduce the cost of 216 
reagents; ii) obtain valuable quantitative information; and iii) extend the measurement range of 217 
the assays. 218 
6. Infrastructure requirements 219 
To develop a portable biosensor system for the rapid diagnosis of CD, first of all, it is necessary to 220 
integrate a transducer with a suitable sensitive bio-chemical layer. Some authors have already 221 
achieved this milestone, as stated in Section 4. Additionally, the system requires the integration of: 222 
i) an electronic read-out system, for the interrogation and signal acquisition; ii) a microfluidic 223 
system, to handle bio-fluids; and iii) a thermal control unit, to keep the temperature stable during 224 
the sample analysis. This last point could be avoided if it is proven that the temperature sensitivity 225 
of the sensor in use is negligible for the experiments we are conducting or if a differential 226 
measurement setup for a temperature compensation is employed (51). Furthermore, it is 227 
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important to mention, that a fully-automated feature is desirable for the complete system, in order 228 
to run the sample analysis as comfortably as possible. 229 
Nowadays, some companies offer commercial solutions for integrated biosensing systems that 230 
could be employed to diagnose CD. However, most of this systems are still of considerable size, 231 
weight and price, which prevents their wide use for field applications in low income communities. 232 
Table 2 shows some integrated biosensing platforms currently available in the market and some of 233 
their features. As can be appreciated in the table, all these systems require to be operated in a 234 
laboratory due to their dimensions. If researchers choose a non-commercial solution, they require 235 
to design and develop a system according to their needs. Nevertheless, this might allow them to 236 
pursuit a more compact, cost-effective and portable system. 237 
Table 2. Different biosensing systems currently available in the market. 238 
Product Company Name Transducer Technology Dimensions (cm) Weight (kg) 
Q-Sense Omega Auto® Q-sense Acoustic 70×67×57 83 
Biacore X100® General Electric SPR 59.6×56.3×59.3 47 
AWS A20-F20® AWsensors Acoustic 77×75×45 60 
OpenPlex®   Horiba SPRi 49×30.4×48 15.6 
7. Conclusions 239 
Since there is not vaccine for CD, currently, the vector control and diagnosis tests are the most 240 
effective methods for preventing the disease and apply effective drug treatments. Even if a 241 
prophylactic or therapeutic vaccine could be achievable in next years, this would need to be part of 242 
integrated efforts that include better diagnostic means, since a vaccine is unlikely to be enough to 243 
stop the parasite transmission. Therefore, highly predictive diagnostic tests are required, not only 244 
to estimate the real size of CD problem, but also to assess the effectiveness of every action 245 
conducted towards a disease burden reduction. 246 
Currently, there are three conventional tests to diagnose Chagas in its chronic phase: IHA, IIF and 247 
ELISA. All of these tests have sensitivities under 100%. Therefore, the WHO recommends 248 
performing at least two of these tests for a conclusive diagnosis, leading to a bottleneck of parasite 249 
detection, caused by limited local availability of laboratories in which such tests can be performed. 250 
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In addition, the diagnosis of the disease is generally delayed due to logistic restrictions of potential 251 
patients to access diagnostic centers. 252 
Non-conventional qualitative tests, like RLF tests, are currently commercially available. Some of 253 
such tests can lead results within minutes, but cannot be considered as conclusive tests by 254 
themselves. Biosensors could be employed to support RLF test results in the future, diminishing the 255 
overall time to achieve definitive quantitative results. Moreover, biosensors could exceptionally 256 
contribute to a fast and secure screening method for blood banks in small and medium health 257 
facilities. Hence, biosensors could improve CD diagnosis and the patients’ treatment follow-up, in 258 
terms of rapidity, small sample volume, high integration, ease of use, real-time and low cost 259 
detection compared to current conventional tests. Pursuing these goals is of considerable 260 
importance and interest to diminish CD burden and to reduce the risk of disease spreading 261 
intensified due to the climate change. Nevertheless, further research efforts are still needed to 262 
develop portable biosensing systems in order to effectively employ this technology for CD 263 
diagnosis. 264 
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